Overweight and Obesity Clinical Trial
Official title:
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
Verified date | December 2023 |
Source | The University of Texas Health Science Center, Houston |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This project investigates the anti-obesity mechanisms of glucagon-like peptide-1 (GLP-1) analogs, which are used in the treatment of human obesity and diabetes mellitus. The investigators will test if GLP-1 induces secretion of interleukin-6 (IL-6), a cytokine that may collaborate with GLP-1 analogs to induce the formation of brown fat, which has anti-diabetic properties. The results will guide future obesity and diabetes mellitus therapies.
Status | Active, not recruiting |
Enrollment | 23 |
Est. completion date | October 6, 2024 |
Est. primary completion date | October 6, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion criteria: 1. Men and women, ages 18-50 years 2. Diagnosis of Prediabetes - defined as either impaired fasting glucose (fasting glucose of 100-125 mg/dL), impaired glucose tolerance (2-hour postprandial blood glucose of 140-199 mg/dL after 75-gram oral glucose challenge), and/or a hemoglobin A1C ranging from 5.5% to 6.4%. 3. BMI = 35 kg/m2 4. Women of childbearing age must agree to use an acceptable method of pregnancy prevention (barrier methods, abstinence, oral contraception, vaginal rings, long-acting reversible contraceptives, or surgical sterilization) for the duration of the study 5. Patients must have the following laboratory values: Hematocrit = 33 vol%, estimated glomerular filtration rate = 60 mL/min per 1.73 m2, AST (SGOT) < 2.5 times ULN, ALT (SGPT) < 2.5 times ULN, alkaline phosphatase < 2.5 times ULN 6. If patients are receiving antihypertensive medications (other than beta blockers) and/or lipid-lowering medications, they must remain on stable doses for the duration of the study. 7. If patients are receiving NSAIDs or antioxidant vitamins, these must be discontinued one week prior to study initiation and cannot be restarted during the study. 8. If patient takes thyroid medications, these must be dosed to control hypo- or hyperthyroidism. Exclusion Criteria: 1. History of Type 1 or Type 2 diabetes mellitus 2. Pregnant or breastfeeding women 3. Medications: Beta blockers, corticosteroids, monoamine oxidase inhibitors, diabetes medications (including incretin mimetics and thiazolidinediones), and/or immunosuppressive therapy over the last 2 months. 4. Uncontrolled hypo- or hyperthyroidism 5. Current tobacco use 6. Active malignancy 7. History of clinically significant cardiac, hepatic, or renal disease. 8. History of any serious hypersensitivity reaction to study medications, any other incretin mimetic, any other formulation of supplemental vitamin B12, and/or cobalt 9. Personal or family history of Leber hereditary optic nerve atrophy 10. Prisoners or subjects who are involuntarily incarcerated 11. Compulsorily detention for treatment of either a psychiatric or physical (e.g., infectious disease) illness 12. Prior history of pancreatitis, medullary thyroid cancer, or multiple endocrine neoplasia type 2 (MEN 2) 13. Serum vitamin B12 level above the upper limit of assay detection |
Country | Name | City | State |
---|---|---|---|
United States | The University of Texas Health Science Center at Houston | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
The University of Texas Health Science Center, Houston |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Interleukin-6 (IL-6) messenger ribonucleic acid (mRNA) (from adipose tissue) | cytokine | 6 weeks after start of each intervention | |
Primary | Uncoupling protein 1 (UCP1) (from adipose tissue) | marker of beige/brown fat | 6 weeks after start of each intervention | |
Primary | Signal transducer and activator of transcription 3 (STAT3) band intensity/Western blot (from adipose tissue) | signaling intermediary with interleukin-6 | 6 weeks after start of each intervention | |
Secondary | PR domain containing 16 (PRDM16) (from adipose tissue) | marker of beige/brown fat | 6 weeks after start of each intervention | |
Secondary | Nicotinamide adenine dinucleotide dehydrogenase (ubiquinone) iron-sulfur protein3 (NDUFS3) (from adipose tissue) | marker of beige/brown fat | 6 weeks after start of each intervention | |
Secondary | Beta1-adrenoceptor (ADRB1) (from adipose tissue) | marker of beige/brown fat | 6 weeks after start of each intervention | |
Secondary | Beta2-adrenoceptor (ADRB2) (from adipose tissue) | marker of beige/brown fat | 6 weeks after start of each intervention | |
Secondary | Beta3-adrenoceptor (ADRB3) (from adipose tissue) | marker of beige/brown fat | 6 weeks after start of each intervention | |
Secondary | Nuclear factor kappa B (NfKappaB) p65 band intensity/Western blot (from peripheral blood mononuclear cells) | signaling intermediary with interleukin-6 | 6 weeks after start of each intervention | |
Secondary | Interleukin-6 (IL-6) mRNA (from peripheral blood mononuclear cells) | cytokine | 6 weeks after start of each intervention | |
Secondary | IL-6 (from peripheral blood mononuclear cells) | cytokine | 6 weeks after start of each intervention | |
Secondary | Suppressor of cytokine signaling 3 (SOCS3) band intensity/Western blot (from peripheral blood mononuclear cells) | signaling intermediary with interleukin-6 | 6 weeks after start of each intervention | |
Secondary | IL-6 (from plasma) | cytokine | 6 weeks after start of each intervention | |
Secondary | Free fatty acids (from plasma) | signaling intermediary with interleukin-6, marker of insulin resistance | 6 weeks after start of each intervention | |
Secondary | Insulin (from plasma) | marker of insulin resistance | 6 weeks after start of each intervention | |
Secondary | Glucose (from plasma) | marker of insulin resistance | 6 weeks after start of each intervention | |
Secondary | Tumor necrosis factor - alpha (from plasma) | cytokine | 6 weeks after start of each intervention | |
Secondary | Interleukin-4 (from plasma) | cytokine | 6 weeks after start of each intervention | |
Secondary | Interleukin-10 (from plasma) | cytokine | 6 weeks after start of each intervention | |
Secondary | Interleukin-11 (from plasma) | cytokine | 6 weeks after start of each intervention | |
Secondary | Interleukin-13 (from plasma) | cytokine | 6 weeks after start of each intervention | |
Secondary | Glucagon-like peptide-1 (from plasma) | incretin | 6 weeks after start of each intervention | |
Secondary | Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | marker of insulin resistance, calculated from fasting plasma glucose and fasting plasma insulin values | 6 weeks after start of each intervention | |
Secondary | Standard Uptake Value (from positron emission tomography - computed tomography (PET-CT) reading) | radiologic marker of brown fat | 6 weeks after start of each intervention | |
Secondary | Oroboros oxygen consumption | measure of oxygen consumption | 6 weeks after start of each intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03994419 -
PErioperAtive CHildhood ObesitY
|
||
Recruiting |
NCT05354245 -
Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL)
|
N/A | |
Completed |
NCT03602001 -
Attentive Eating for Weight Loss
|
N/A | |
Recruiting |
NCT06269159 -
The Power of 24-hour: Co-designing Intervention Components
|
||
Completed |
NCT03377244 -
Healthy Body Healthy Souls in the Marshallese Population
|
N/A | |
Completed |
NCT02996864 -
Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II
|
N/A | |
Completed |
NCT04647149 -
Effects of Early and Delayed Time-restricted Eating in Adults With Overweight and Obesity
|
N/A | |
Terminated |
NCT03914066 -
A Group-based Treatment of Overweight and Obesity in Primary Care
|
N/A | |
Completed |
NCT03685656 -
Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers
|
N/A | |
Completed |
NCT05051579 -
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
|
Phase 2 | |
Completed |
NCT04611477 -
Effect of Synbiotic 365 on Body Composition in Overweight and Obese Individuals
|
N/A | |
Active, not recruiting |
NCT05330247 -
Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study
|
N/A | |
Completed |
NCT03599115 -
Effects of Inhibitory Control Training in Eating Behaviors
|
N/A | |
Recruiting |
NCT05938894 -
Train Your Brain - Executive Function
|
N/A | |
Recruiting |
NCT06094231 -
Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study
|
N/A | |
Recruiting |
NCT05987306 -
A Self-compassion Focused Intervention for Internalized Weight Bias and Weight Loss
|
N/A | |
Completed |
NCT03792685 -
Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention
|
N/A | |
Completed |
NCT05055362 -
Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study
|
N/A | |
Completed |
NCT04520256 -
Rapid Evaluation of Innovative Intervention Components to Maximize the Health Benefits of Behavioral Obesity Treatment Delivered Online: An Application of Multiphase Optimization Strategy
|
Phase 2/Phase 3 | |
Completed |
NCT04979234 -
A Single Centre, Prospective Feasibility Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina) on Severe Obstructive Sleep Apnea Syndrome
|
N/A |